Related Experiment Video

Updated: May 23, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Emerging role of PKA/eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases

Shyamal C Bir1, Yan Xiong, Christopher G Kevil

  • 1Department of Pathology, LSU Health Sciences Center-Shreveport, LA, USA.

Cardiovascular Research
|April 12, 2012
PubMed

Insights

Understanding nitric oxide (NO) and protein kinase A/endothelial NO synthase (PKA/eNOS) signaling is crucial for improving therapeutic angiogenesis in ischemic conditions. This review explores these pathways to identify novel treatments for neovascularization.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Biomedical Science

Background:

  • Angiogenesis research is extensive, yet precise mechanisms remain unclear.
  • Clinical trials for therapeutic angiogenesis in tissue ischemia show limited success compared to preclinical findings.
  • Further research into molecular mechanisms of ischemic neovascularization is vital for developing new therapies.

Purpose of the Study:

  • To review recent advances in the PKA/eNOS and NO-cGMP-kinase cascade pathway in ischemic neovascularization.
  • To discuss the molecular interplay between PKA/eNOS and other angiogenic pathways.
  • To explore the potential of activating the NO/nitrite endocrine system as a therapeutic strategy for ischemic angiogenesis.

Main Methods:

  • Literature review focusing on PKA/eNOS signaling in neovascularization.
  • Analysis of molecular mechanisms regulating ischemic angiogenesis.
  • Exploration of therapeutic targets within the NO-cGMP-kinase pathway.

Main Results:

  • Nitric oxide (NO) is central to ischemic neovascularization via cGMP generation and other signaling.
  • The PKA/eNOS pathway is implicated in promoting neovascularization in ischemic disorders.
  • Interactions between PKA/eNOS and other angiogenic pathways are significant.

Conclusions:

  • The PKA/eNOS and NO-cGMP-kinase pathway is critical for ischemic neovascularization.
  • Understanding these pathways can lead to novel therapeutic agents for ischemic diseases.
  • Targeting the NO/nitrite endocrine system offers a promising avenue for therapeutic angiogenesis.

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...